In a report (I Hirano, ES Dellon et al. Gastroenterol 2020; 158: 111-22) on a phase 2 trial with 47 adults, the authors show that weekly subcutaneous injections of dupilumab (300 mg) was associated with improvement in eosionophilic esophagitis.
Dupilumab, a fully human monoclonal antibody, antagonizes the interleukin-4 receptor-alpha component of the type 2 receptor, thereby inhibiting signaling of IL-4 and IL-13. Dupilumab has shown “efficacy in pediatric and adult atopic dermatitis, asthma, and chronic sinusitis with nasal polyposis” and is FDA-approved for use in these disorders.
- Dupilumab was associated with improvement in dysphagia as measured by the Straumann Dysphagia Instrument with a mean reduction of 3.0 compared to 1.3 in the placebo group at week 10 (P=.0304)
- Dupilumab was associated with improvement in histology, at week 12, the peak eosinophil count had dropped by a mean of 86.8 (P<.0001 vs. placebo)
- Dupilumab was associated with improvement in endoscopic parameters as assessed by endoscopic reference score which dropped by 1.6 (P -.0006 vs placebo)
- No serious adverse effects were evident. Nasopharyngitis was noted in 17% in the dupilumab group compared to 4% of placebo-treated patients. Injection site erythema was noted in 35% (vs. 8% in placebo group
Of note, the study was sponsored by pharmaceutical companies and many of the authors (including both lead authors) were either affiliated with these companies.
My take: This study indicates that Dupilumab has at least short term efficacy and safety for eosinophilic esophagitis.
Related blog posts:
- Promising Biologic for Eosinophilic Esophagitis
- Transnasal Endoscopy (Unsedated) for EoE
- How Genetics Influence Response Rate to PPIs in EoE
- Association and Causation: Early Life Risk Factors for Eosinophilic Esophagitis
- Negligible Effect of Eosinophilic Esophagitis Treatment on Longitudinal Growth
- Increased Risk of EoE with TEF/EA
- What is EoE?
- EoE Update 2018 (Dr. Seth Marcus)
- Updated Consensus Guidelines for Eosinophilic Esophagitis
- Time to Diagnosis in Eosinophilic Esophagitis
- Adrenal Insufficiency due to Fluticasone in EoE
- Higher Doses of Topical Steroids for Eosinophilic … – gutsandgrowth
Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition
Pingback: Could Immunotherapy (EPIT) Work For Eosinophilic Esophagitis? & Coronavirus Up-to-Date Tally | gutsandgrowth
Nice articles, but in some case is some one with Gerd history and then infected coronavirus, will the coronavirus makes the gerd worst?
I have not seen any publications on this. Generally, viral infections increase GI symptoms.
Pingback: Eosinophilic Esophagitis -Up to Date Dietary Management Review | gutsandgrowth
Pingback: How Effective Are PPIs for Eosinophilic Esophagitis? | gutsandgrowth